Study: 18F-FLT helps track patients' response to treatment

10/8/2009 | HealthImaging.com

An Australian study that compared results of baseline PET/CT scans using the 18F-fluorothymidine tracer with routine staging 18F-FDG PET/CT scans found that 18F-FLT allowed for monitoring of changes in the cellular spread of nonsmall-cell lung cancer during chemo-radiotherapy. The findings show that the 18F-FLT tracer could be useful in improving NSCLC treatments based on patients' response.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY